Cell-associated levels of aromatic gut-derived bacterial metabolites (GDBMs) — not their circulating plasma concentrations — correlate with profound alterations in CD4+ T cell metabolism and function in people living with HIV-1 (PLWH). The compound p-cresol sulfate (PCS) emerged as the mechanistic focal point: single-cell RNA sequencing and flow cytometry stratified by intracellular PCS showed dose-dependent enrichment of senescence programs, regulatory-like T cell identity, and impaired differentiation. In vitro exposure confirmed cell-cycle arrest, mitochondrial dysfunction, and upregulation of canonical senescence markers p16 and p21. Crucially, these GDBM-defined CD4+ T cell states tracked with intact proviral HIV-1 DNA levels in vivo.
The finding that intracellular — rather than systemic — metabolite burden drives immune dysfunction is conceptually important. It reframes microbiome research away from plasma metabolomics toward cellular uptake and compartmentalization, a distinction most prior studies have overlooked. For the broader aging field, PCS is already recognized as a uremic toxin accumulating with gut dysbiosis and kidney decline, but its role in T cell immunosenescence has been undercharacterized. This work draws a compelling mechanistic line from gut microbiome composition through a specific metabolite to accelerated immune aging and viral reservoir maintenance — two of the most stubborn obstacles in HIV cure research. Limitations include the observational design and HIV-specific cohort, which restricts immediate generalizability. Whether PCS-mediated senescence operates similarly in non-HIV immune aging warrants direct investigation. Paradigm-shifting in framing; causal confirmation in human trials remains the critical next step.
